-
ABOUT US
-
R&D
-
AGORA
-
PR
-
RECRUITMENT
-
CONTACT
AGORA
2024-2026
| Stage | 2024 | 2025 | 2026 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| US FDA Investigational New Drug (IND) submission milestones of 3HOTP | ||||||||||||
| Non-Clinical Study |
|
|
|
|
||||||||
| Pre-IND Activity |
|
|
|
|||||||||
| Pre-IND Meeting | ||||||||||||
| IND Preparation & Submission |
|
|||||||||||
| Phase I Clinical Study |
|
|
|
|
||||||||
| Phase II Clinical Study |
|
|
|
|
||||||||
| US FDA New Animal Drug Application (NADA) milestones of 3HOTP | ||||||||||||
| Preliminary Animal Study |
|
|
||||||||||
| Open INAD & Pre-submission Conference (PSC) |
|
|
|
|||||||||
| Pivotal Target Animal Study |
|
|
|
|
|
|
|
|||||
| NADA |
|
|
||||||||||